#Mazdutide
LightNews LightNews
hswapnil.medsky.social
New GLP1RA (+glucagon agonist) drops, from China - mazdutide

www.nejm.org/doi/full/10....
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight | NEJM
Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...
www.nejm.org
May 26, 2025 at 10:29 AM
samillingworth.com
💊 Weight loss drug beats placebo tenfold

Over 60 weeks, adults with obesity taking weekly mazdutide lost 16.65% of body weight, against 1.5% on placebo. Most on the drug had gut side effects.

🔗 doi.org/10.1001/jama.2026.8142

#Obesity #Medicine #Health 🧪
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
This randomized clinical trial compares the efficacy and safety of a 9-mg dose of mazdutide vs placebo in Chinese adults with obesity.
doi.org
August 5, 2026 at 5:14 AM
drkarlnadolsky.bsky.social
In Chinese adults with overweight or obesity, once-weekly #GLP/glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 - 48 weeks, led to clinically relevant #weightloss in the GLORY-1 trial.
Very low drop out rates due to side effects

www.nejm.org/doi/full/10....
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight | NEJM
Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...
www.nejm.org
May 25, 2025 at 9:17 PM
danieljdrucker.bsky.social
Mazdutide, via its dual GLP-1/GCGR activation effects, exerts multifactorial neuroprotective-related improvements in cognitive function in male db/db mice id.elsevier.com/as/authoriza...
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis
Our findings indicate that mazdutide, via its dual GLP-1/GCGR activation effects, exerts multifactorial improvements in cognitive function in the context of obesity and T2DM. These results suggest tha...
id.elsevier.com
June 8, 2025 at 1:57 PM
nejm.org
GLORY-1 trial: Obesity and overweight are well-recognized risk factors for a range of diseases. Research evaluating the efficacy and safety of mazdutide in long-term weight management is summarized in a short video. nej.md/4l6zMZP

#MedSky #EndoSky #GastroSky
An illustration of a patient with obesity or with overweight and mazdutide, a once-weekly glucagon-like peptide-1 and glucagon receptor dual agonist, for long-term weight treatment.
June 15, 2025 at 7:01 PM
danieljdrucker.bsky.social
Clinically meaningful #weightloss data for Mazdutide in China, expanding options for GLP-1 medicines. Will survodutide be the first glucagon-GLP-1 medicine to report a CV outcomes trial?
May 25, 2025 at 10:36 PM
jama.com
💬 Editorial: Mazdutide and orforglipron demonstrate clinically meaningful benefits for #Obesity and #Diabetes, with gastrointestinal events as a key tolerability consideration.

#ADA2026 @adapubs.bsky.social

ja.ma/4e5zfFg
JAMA article: Editorial titled "Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes" by Kishore M. Gadde, Jonanne Talebloo, and Steven B. Heymsfield. Published online June 7, 2026. DOI: 10.1001/jama.2026.10443.
June 7, 2026 at 8:25 PM
nejm.org
Presented at the Peking University Diabetes Forum:

Once-weekly mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY-1 trial results: nej.md/4koUvaP
May 25, 2025 at 5:11 PM
nejm.org
Once-weekly mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with #obesity or overweight. Full GLORY-1 trial results: nej.md/4koUvaP 

#MedSky #EndoSky
The New England Journal of Medicine Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight A Research Summary based on Ji L et al. | 10.1056/NEJMoa2411528 | Published on May 25, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
June 18, 2025 at 7:20 PM
jama.com
📊 Research Summary: Once-weekly 9-mg mazdutide led to 17% mean weight loss vs 2% with placebo among Chinese adults with #Obesity, but most recipients reported mild or moderate gastrointestinal symptoms.

#ADA2026 @adapubs.bsky.social

ja.ma/4fpkKP9
JAMA Research Summary: Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity. A trial with 307 Mazdutide & 154 Placebo patients showed Mazdutide group lost 16.65% body weight (84.3% had reduction) vs placebo's 1.50% (33.1% reduction).
June 7, 2026 at 1:10 PM
jama.com
Among Chinese adults with #obesity, 84% receiving mazdutide lost ≥5% body weight at 60 weeks; vomiting, nausea, and diarrhea were the most common mild to moderate adverse events.

#ADA2026 @adapubs.bsky.social

ja.ma/4fuI0LG
JAMA study on Mazdutide for weight reduction in Chinese adults with obesity. Mazdutide led to -16.65% weight reduction (84.3% responders) vs. placebo's -1.50% (33.1% responders) but had GI adverse reactions. Study included 461 adults (mean age 34) from 27 hospitals.
June 7, 2026 at 1:05 PM
midgardfinance.com
💊 #pharma #MCP Our obesity and incretin trial data is now an MCP server. Ask Claude Code, get estimand-tagged answers with a citation. Free.

Why it matters: the same trial reports two weight-loss numbers, up to 3.6pp apart. Twelve do.

mcp.midgardfinance.com

#$LLY 🇺🇸 #$NOVO 🇩🇰
Grouped bar chart of twelve obesity drugs, each with two bars for the same trial. The blue bar is the on-treatment (efficacy) estimand, the purple the treatment-policy estimand, both as percentage of body weight lost. Retatrutide is deepest at 28.3 against 25.0, then CagriSema 22.7 against 20.4, Zepbound 22.5 against 20.9, Wegovy HD 20.7 against 18.7, Ribupatide 19.2 against 17.7, Mazdutide 18.6 against 16.7, Bofanglutide 17.3 against 16.7, Wegovy 16.9 against 14.9, Survodutide 16.6 against 13.0, Wegovy pill 16.6 against 13.6, Ecnoglutide 14.1 against 13.2 and Foundayo 12.4 against 11.2. The on-treatment figure is higher in every case. Each pair is the top dose of that drug in the trial named, and trial durations differ, from 30 to 80 weeks, so the comparison that matters is within each pair rather than between drugs.
September 27, 2026 at 7:00 AM
thelancetendo.bsky.social
Multihormone receptor modulators that include #glucagon receptor agonism—such as #mazdutide—could provide novel & effective alternatives for weight management, further expanding the options available for optimised treatment of individuals with #obesity www.thelancet.com/journals/lan...

#MedSky
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
Once-weekly, subcutaneous mazdutide showed clinically meaningful bodyweight reduction in adults with obesity or overweight across all studied doses, with higher doses (10 mg and 16 mg) showing additio...
www.thelancet.com
September 24, 2026 at 7:48 AM
centinel.bsky.social
Ensayo de un agonista GLP-1 desarrollado en China, con buenos resultados de pérdida de peso (sobre 10%).
www.nejm.org/doi/abs/10.1...
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight | NEJM
Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...
www.nejm.org
July 12, 2025 at 11:07 AM
newsen.bsky.social
Innovent's Mazdutide Clinical Results: A Revolutionary Impact on Type 2 Diabetes Treatment in China#China#Suzhou#Innovent_Biologics#Type_2_Diabetes#Mazdutide
Innovent's Mazdutide Clinical Results: A Revolutionary Impact on Type 2 Diabetes Treatment in China
Innovent Biologics announces two groundbreaking Phase 3 clinical trials of Mazdutide, a dual receptor agonist for type 2 diabetes, published in Nature.
third-news.com
December 18, 2025 at 12:11 AM
medicine.stitches.today
Once-weekly mazdutide significantly reduced body weight in overweight Chinese adults, showing promise for obesity treatment.

by Ji L, Jiang H (...) Qian L et 20 al. in N Engl J Med #MedSky

👉 get more here

📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2411528
June 21, 2025 at 12:54 PM
francesari.bsky.social
Two registered clinical trials in Nature report the successful use of the GLP-1 and glucagon receptor co-agonist Mazdutide for type 2 diabetes.🧪
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Mazdutide versus placebo in Chinese adults with type 2 diabetes - Nature
Nature - Mazdutide versus placebo in Chinese adults with type 2 diabetes
www.nature.com
December 18, 2025 at 11:41 AM
some-news.bsky.social
Mazdutide is a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) 1. This study assessed the efficacy and safety of mazdutide versus dulaglutide in participants with T2D on background oral anti-diabetic drugs. In this..
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes - Nature
www.nature.com
December 18, 2025 at 5:12 AM
handle.invalid
China approves mazdutide—the world’s first dual GLP-1/glucagon drug—for chronic weight management. In trials: nearly 15% average weight loss at 48 weeks! A big step for incretin therapies as China tackles its growing obesity crisis.
July 7, 2025 at 3:38 PM
fintwitter.bsky.social
INNOVENT BIOLOGICS CFO: EXPECT MAZDUTIDE APPROVAL FOR DIABETES INDICATION IN A COUPLE OF MONTHS
August 27, 2025 at 1:22 PM
nejm.org
Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1 trial) nej.md/4koUvaP

AAV Gene Therapy in Severe Hemophilia B nej.md/3T7nxQN

Brief Report: Bespoke Base Editing for Genetic Disease nej.md/42XF03F

Subscribe to NEJM for the latest medical research: nej.md/subscribe
June 12, 2025 at 1:24 PM
thelancetendo.bsky.social
New—Efficacy and safety of #mazdutide in adults with #obesity or #overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial thelancet.com/journals/lan...
#GLP-1 #glucagon

#MedSky #EndoSky
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
Once-weekly, subcutaneous mazdutide showed clinically meaningful bodyweight reduction in adults with obesity or overweight across all studied doses, with higher doses (10 mg and 16 mg) showing additio...
thelancet.com
August 22, 2026 at 7:21 AM
dietistarealista.bsky.social
🔵 Semaglutide oral (Rybelsus)
🔵 Tirzepatide (Mounjaro)
🔴 Orforglipron (Foundayo)

En desenvolvemento/non aprobados:
🔵 Retatrutide
🔵 Danuglipron
🔵 Amycretin
🔵 Monlunabant
🔵 Cagrilintide-semaglutide (Cagri-Sema)
🔵 Ecnoglutide (XW003)
🔵 Mazdutide (IB1362)
🔵 Survodutide
April 3, 2026 at 11:43 AM
handle.invalid
Read more: https://www.fiercepharma.com/pharma/china-approval-lilly-and-innovents-mazdutide-breaks-new-class-glp-1-obesity-drugs
China Approves First Dual GLP-1/GCG Obesity Drug Class
www.fiercepharma.com
July 7, 2025 at 3:38 PM
cafepharma.bsky.social
Mon news: Novartis shares slip on $12B deal to buy Avidity. Innocent/Lilly’s mazdutide beats Novo in head-to-head. MapLight IPO to fund BMS competitor. Organon CEO resigns amid internal investigation. Intellia plummets on paused trial. —https://bit.ly/3JeBlY5
October 27, 2025 at 4:07 PM